Member Info for PL75

I’m not that excited by case studies and boosting. It just brings volatility and a plethora of twats. We’ve got enough already. I’m waiting for the first two and sustained share price growth. Seeing the data is the first step.

Not a dig CTSFO, I’ve enjoyed your contributions. I imagine he was thinking of expensive therapies. Dox remains the SoC and as Dr Tap has said, it’s not going anywhere soon - except where it gets replaced overnight for certain cancer types of course…

Olaratumab Is Lartruvo, given accelerated approval and was earning the annual equivalent of $2bn before they figured out it didn’t work.

That note was spewed out the backside of someone lacking basic research, not sure why anyone is interested really.

Who on earth hasn’t binned LDA? Board clogger extraordinaire.

Thanks crowfoot. I re-read the RNS and as is often the case, it’s ambiguous. There’s talk of trial redesign and releasing data but they’re not explicitly linked. If it was clearer in the Q&A and I’ve missed that, all good. We’ll find out soon enough

Alan said it in the RNS, but Eggy likes to ignore facts and listen to the voices in his deranged head instead

A few people are speculating he left due to ill health. Sh.t happens. Has it caused any issues with the trial? Fiona, the FDA, Dr Tap and the rest not up to the job? Sounds like FUD if it’s a baseless ‘concern’ or more accurately a weird obsession. Remember the goal is to get a useful drug to market, not endless scientific masturbation. Expediting is 100% a good thing. It’s faster and cheaper.

Rhyming slang?

Morning Eggy, so you’re not worried about Neil Bell. Lucky him, I’d hate to have him harassed by an obsessive weirdo. You are worried about your own made up quote though.

‘We need to do 1a properly and it'll take as long as it takes to give us the information we need. Only then can we ensure that the rest of the trial gives us optimal results we're hoping for.'

They’ve got the information they need. It’s safe. It works. They’re moving on.

They’ve departed ways with a Csuite colleague. Hardly the first time that’s happened. They now want a CMO as the business is evolving. Good. We move on. Well, most normal humans do.

Doc Tap said chemo is not going anywhere as it works. That was my takeaway.

What’s better than chemo…. Chemo without the side effects. It’s a platform.

Worry all you want about your beloved bell weirdo. They’ve already extended 1a way beyond their initial expectations. They’ve learnt everything they need to in order for the safety committee to agree it’s time to move on as they’re not only confident it’s safe but they’ve seen clear efficacy. It’s a commercial business, their recent decisions have been the first time they’ve properly acted like one. Expediting is the best outcome for the business and with thorough oversight from Dr Tap, other experts in the other trial hospitals, the FDA, the safety committee they’re also aiming for the best outcome for patients in getting it to market as soon as they can.

No need to worry about that, he can’t raise his crippled hands due to his wrecked joints

Did someone accidentally put a twat signal in the sky?

Exactly gmcc. Alan said it’s a quick process to get approval, where quick equated to a couple of months. It could be announced any day and is independent of releasing data.

The ‘impression’.

They've changed their strategy. Previously it was following 1a, peer reviewed to make the biggest splash, now it's gather up whatever is lying around - check it's correct - bosh it out in Q4. Only Sujood knows why, but I'm sure there are good reasons - the obvious being that the data package proves beyond all possible doubt the platform works and they'd like to do some deals.

Alan recently only mentioned a QA rather than a peer review. They've changed their strategy and are now determined to publish the C1-7ish data in Q4. Only Sujood knows why.

Yup, loads of things move the share price, I’m waiting for it to move significantly in the right direction. Nov 21st is approaching fast.

The brokers currently have us valued at over 2 quid. A broker note won’t make a difference. Data, along with case studies will move the needle. External validation by a customer is what deliver the re rate. That what I think anyway.

Alan says over 50%, but he also said the brokers won’t change theirs.

4 times 10%, but bear in mind it was written by the human equivalent of Yahoo Finance and he made that up.